Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30318460 | 1.00 | GPR119 (0.45) | GPR119USP30SRCIDO1TDO2 | |
| SCHEMBL29115044 | 0.93 | GPR119 (0.42) | GPR119USP30SRCIDO1TDO2 | |
| SCHEMBL29114989 | 0.93 | GPR119 (0.42) | GPR119USP30SRCIDO1TDO2 | |
| SCHEMBL30318697 | 0.93 | FPR2 (0.48) | USP30FPR2KMT2A | |
| SCHEMBL30318315 | 0.93 | FPR2 (0.48) | USP30FPR2KMT2A | |
| SCHEMBL2386226 | 0.93 | GPR119 (0.51) | GPR119NR3C1DDB1CRBNPTPN2 | |
| SCHEMBL22118568 | 0.90 | FPR2 (0.42) | GPR119USP30FPR2 | |
| SCHEMBL31675895 | 0.88 | HPGD (0.48) | GPR119NR3C1DDB1CRBNPTPN2 | |
| SCHEMBL30318354 | 0.88 | HPGD (0.48) | GPR119NR3C1DDB1CRBNPTPN2 | |
| SCHEMBL30318195 | 0.88 | HPGD (0.48) | GPR119NR3C1DDB1CRBNPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4301468-B1 | FGFR3 INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250122196-A1 | FGFR3 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2025-04-17 | — | — | US | disclosed |
| US-12209086-B2 | FGFR3 inhibitor compounds | ELI LILLY AND COMPANY (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240190870-A1 | FGFR3 INHIBITOR COMPOUNDS | LOXO ONCOLOGY, INC. | 2024-06-13 | — | — | US | disclosed |
| US-11878976-B2 | FGFR3 inhibitor compounds | ELI LILLY AND COMPANY (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230095122-A1 | FGFR3 INHIBITOR COMPOUNDS | LOXO ONCOLOGY, INC. | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11878976-B2 | FGFR3 inhibitor compounds | FGFR3, FGFR1, FGFR2 | GPR119 2204/4885USP30 1644/4885SRC 963/4885 |
| US-12209086-B2 | FGFR3 inhibitor compounds | FGFR3, FGFR1, FGFR2 | GPR119 2204/4885USP30 1644/4885SRC 963/4885 |
| US-20240190870-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | GPR119 2204/4885USP30 1644/4885SRC 963/4885 |
| US-20250122196-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | GPR119 2204/4885USP30 1644/4885SRC 963/4885 |
| US-20230095122-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | GPR119 2204/4885USP30 1644/4885SRC 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.